Treatment News : Hep B or C Coinfection Spells Worse Response to HIV Meds

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2013

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 22, 2013

Hep B or C Coinfection Spells Worse Response to HIV Meds

People with HIV who are coinfected with either hepatitis B or C virus (HBV/HCV) experience diminished response to antiretroviral (ARV) treatment for HIV and have a greater risk of death when compared with those monoinfected with HIV, reports. Investigators analyzed data from the TREAT Asia HIV Observational Database on 7,455 HIV-positive study participants receiving treatment at 22 Asian clinics. Out of those participants with test results that were evaluable, 10.45 percent were coinfected with hep B and 15.2 percent with hep C. The researchers presented their findings at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

After the participants had been treated with ARVs for 180 days, those coinfected with hep B had an average of 15.5 fewer CD4 cells and those coinfected with hep C had 37.8 fewer CD4s when compared with monoinfected participants.

The median length of time those in the study took to reach the target viral load of less than 1,000 was 1.28 years. The coinfected participants took longer to reach this point, although the difference was not statistically significant, meaning that it could have occurred by chance.

However, coinfected participants did have a significantly greater mortality risk: an 80 percent greater likelihood of dying than those with only HIV.

To read the Healio story, click here.

To read the conference abstract, click here.

Search: HIV, hepatitis B, hepatitis C, coinfection, antiretroviral treatment response, CD4 cells, monoinfection, TREAT Asia HIV Observational Database, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013, risk of death.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.